CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[Y] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

A good review. I think informative Table that shows mechanism and clinical/experimental outcome of each immunotherapy (peptide, DC, whole tumor cell, viral vector, and their combination) is necessary and important.

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 5409
Title: Immunotherapy for colorectal cancer
Reviewer code: 00227435
Science editor: Ma, Ya-Juan
Date sent for review: 2013-09-06 18:23
Date reviewed: 2013-09-27 16:18

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ] Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[Y] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

Overall the review article is well presented with good coverage of sections of the relevant literature and is written in a clear style for the non-specialist. Suggestions for revision and improvement are: 1. The description on regulatory T cells is superficial and does not account for the all of these cell types. No mention is made of gamma-delta T cells or NK cells (See recent review in Cell Mol. Immunol.) which have been used as an experimental cancer therapy in humans. There is also no mention of adoptive T cell transfer therapy for cancer. 2. Antibody-based cancer immunotherapy is not noted in any detail and cytokine therapy is mentioned only in passing as an adjuvant therapy. 3. The manuscript is very text dense and would benefit from the inclusion of additional tables and/or figures. 4.The future developments of immunotherapy needs to better addressed providing a clearer idea of what new types of therapy are in development and the direction being taken for the discovery of new therapies.